Navigation Links
Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
Date:5/15/2008

ATTRIBUTABLE TO

COMMON STOCKHOLDERS PER SHARE:

BASIC $(0.57) $(0.16)

DILUTED $(0.57) $(0.16)

WEIGHTED AVERAGE SHARES OUTSTANDING:

BASIC 21,379,638 10,697,702

DILUTED 21,379,638 10,697,702

PHARMASSET, INC.

CONDENSED BALANCE SHEETS

As of As of

March 31, September 30,

2008 2007

(unaudited)

----------------------------------

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $62,961,991 $68,745,694

Short-term investments 1,224,489 1,252,113

Amounts due under collaborative

agreements 1,477,434 919,110

Prepaid expenses and other assets 954,977 783,311

----------------------------------

Total current assets 66,618,891 71,700,228

----------------------------------

EQUIPMENT AND LEASEHOLD IMPROVEMENTS:

Laboratory, office furniture and

equipment 3,074,611 2,462,647

Leasehold improvements 1,836,553 1,836,553

----------------------------------

4,911,164 4,299,200

Less accumulated depreciation and

amortization (1,924,661) (1,437,080)


'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
2. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
3. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
4. Pharmassets Underwriters Release Shares from Lock-Up
5. Nephros Reports 2008 First Quarter Financial Results
6. PreMD Reports First Quarter Results
7. Lifeway Foods Reports Record 1st Quarter 2008 Results
8. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
9. Tiens Biotech Group (USA) Reports First Quarter Results
10. Cardiogenesis Reports First Quarter 2008 Results
11. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...ence Call Scheduled Tuesday, August 5, 2008 at 11:...e-FirstCall/ -- Almost Family, Inc.,(Nasdaq: AFAM...sing,services, announced today that it will report..., 2008 on Tuesday, August 5, 2008, before the,mark... will begin at 11:00 a.m. ET on,August 5, 2008 and...
(Date:7/23/2008)...ON, N.J., July 23 /PRNewswire-USNewswire/ -- The N...lity and Patient Safety has,received a planning gr...dation (RWJF) to develop a proposal for improving ...nt will help determine over the next six months wh...ning Forces for Quality initiative,which is focus...
(Date:7/23/2008)..., China, July 23 /Xinhua-PRNewswire-FirstCall/ -- ...letin Board: GTEC) ("Genesis" or,the "Company"), a...public,of China, held a Board of Directors meeting...appointed to serve on the Board of Directors of th...on Committee were formed., Mr. Michael Marks was ...
(Date:7/23/2008)...ERSBURG, Fla., July 23 /PRNewswire/ -- Laura Kolkm...gnized health information exchange,consulting firm...hcare,Information and Management Systems Society (...ing Committee., The HIE Steering Committee, which...ng providers, payers, vendors, consultants and lif...
Breaking Medicine News(10 mins):Health News:Almost Family, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2
...to be the first malarial outbreak in 40 years, hea...have come down with malaria.// No fresh cases of ...he major resort locations are free of the infectio...s one of the world‘s deadliest diseases, killing a...
...risk factor for cardiovascular diseases.A potbelly...re even if the rest of the body is skinny as a bea...ctor of risk is the relationship of waist size to ...atio predicts an increased risk of heart attack. T...
...ts plea to doctors over prescription of cheaper dr...ions in the coming year if GPs// prescribed cheape...s (PCTs) can prescribe generic versions of the dru...e two of five ‘statin’ drugs that are approved for...
... potential beneficial effects of TNFa inhibition i...anti-TNFa treatment in aging," appears in the Janu...his study shows hope for significantly reducing va...TNFa, which has been linked to blood vessel dysfun...
Other Medicine News:Health News:Pot Belly Is A Better Risk Predictor Of Heart Attack Than BMI 2Health News:Effects Of Age-related Vascular Diseases Can Be Reduced By Inactivating TNFa 2
(Date:7/22/2008)...lidated by Columbia University Medical Center Base...RNA Technology, The Test Differentiates Squamous...CLC), Classifying Squamous-Cell Carcinoma of the L...ificity of 90 Percent,This is the First CLIA Appro... as Biomarkers for Accurate Diagnosis of Lun...
(Date:7/22/2008)... France, July 22 /- NicOx S...uccessfully completed the,enrollment of 417 osteoa...n,in two clinical pharmacology studies in the Unit...ines. These trials are designed to assess the,bloo...o ibuprofen and,naproxen, using the Ambulatory Blo...
(Date:7/22/2008)...sts That Ekkyo,s New Approach of LASH (Laser Assis... Healing Physiology, MARSEILLES, France, July 22 ...Technology) a photomedicine company, which develop... prevention and reduction, announced today,the pub...ery and Medicine*,reporting the results of a pilot...
(Date:7/21/2008)... /- Ari Kiev, M.D., president of SPRI...e upcoming conference Wall,Street Unplugged: The T...to,Wall Street. The conference will be held on Wed...fth Avenue in New York. The event is targeted to C... science companies to gain,better insight into Wal...
Breaking Medicine Technology:First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Health Fitness Completes Share Repurchase Plan 20254 1Health Fitness Completes Share Repurchase Plan 20254 2Current vitamin D recommendations fraction of safe perhaps essential levels for children 20248 1Current vitamin D recommendations fraction of safe perhaps essential levels for children 20248 2ev3 Inc to Present at the Goldman Sachs Twenty Ninth Annual Global Healthcare Conference 20245 1Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI COR Biosciences 5622 1Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI COR Biosciences 5622 2Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI COR Biosciences 5622 3
... Disease Week -, CAMBRIDGE, Mass., May 21, 2007 /P...ation of data from a Phase 2 study in which,linacl...el function,in patients with constipation- predomi...also showed linaclotide was well tolerated with,a ...first-in-class,compound currently being developed ...
...ts from phase III,clinical trials and further huma...Congress of the European Academy of,Dermatology an...fficacy and safety profile of alitretinoin as a po...h severe refractory chronic,hand eczema. , Current...c Hand,Eczema (CHE) refractory or unresponsive to ...
Other Medicine Technology:Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 2Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 3Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5
...ue processor features superior user comfort with s...closed, stand-alone system for processing of up to...ocessor combines proven technology with an innovat... use,yet powerful software. Many routine user oper...
...mily are semi-enclosed tissue processors. The Leic...nology with modern and functionally enhanced desig...or tissues at all stages of the processing run, ro...mechanics in conjunction with a modern user interf...
...w tissue infiltration instrument, which combines w...erly way. The robust caroussel design is proven an... instrument includes either 10 reagent and 2 paraf...ers. Up to 10 different programs can be stored all...
...with automatic fine/trim- feed system, specimen re...ecision cross roller bearings. For sectioning para...in biological, botany, and materials science. Spec...Performance, ergonomy and design of this sliding m...
Medicine Products: